Analysts Offer Insights on Healthcare Companies: Viewray (NASDAQ: VRAY) and Crispr Therapeutics AG (NASDAQ: CRSP)

By Ryan Adsit

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Viewray (NASDAQ: VRAY) and Crispr Therapeutics AG (NASDAQ: CRSP).

Viewray (NASDAQ: VRAY)

Mizuho Securities analyst Difei Yang assigned a Buy rating to Viewray (NASDAQ: VRAY) today and set a price target of $12. The company’s shares closed on Friday at $8.51.

Yang said:

“We are not too concerned because the of usual lumpiness at the beginning of new operations. Management remains confident it can complete installation of 7-8 units before year-end. On the positive side, new orders received grew to $29.9 mil vs. our est. of $24.3 mil. Given the favorable development in Europe, Q4 back orders may exceed our expectations.”

According to, Yang is a 5-star analyst with an average return of 14.6% and a 51.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Fennec Pharmaceuticals Inc, and Spectrum Pharmaceuticals.

Viewray has an analyst consensus of Moderate Buy, with a price target consensus of $9.50.

Crispr Therapeutics AG (NASDAQ: CRSP)

In a report released today, Leah R. Cann from Oppenheimer assigned a Hold rating to Crispr Therapeutics AG (NASDAQ: CRSP). The company’s shares closed on Friday at $17.45.

R. Cann noted:

“CRISPR Therapeutics announced today that its joint venture with Bayer, Casebia Therapeutics, and CureVac AG, a biopharmaceutical company pioneering mRNA- based drugs, have signed a collaboration agreement. It was reported that CureVac will provide mRNA manufacturing through clinical development and commercialization of the three programs in the agreement. In exchange, CureVac will receive an upfront payment and research funding, and will be eligible to receive development and commercial milestones and royalties on commercialized products arising from the collaboration.”

According to, Cann is a 4-star analyst with an average return of 8.9% and a 46.7% success rate. Cann covers the Healthcare sector, focusing on stocks such as CytomX Therapeutics Inc, Intellia Therapeutics, and Syros Pharmaceuticals.

Currently, the analyst consensus on Crispr Therapeutics AG is Moderate Buy and the average price target is $22.50, representing a 28.9% upside.

In a report issued on November 9, SunTrust Robinson also reiterated a Hold rating on the stock with a $16 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.